Immune science

Recovered COVID-19 individuals can have SARS-CoV-2 antibodies for at least 6 months

In a recent publication in Viruses, Dr. Ishac Nazy from McMaster University finds that SARS-CoV-2 antibodies against the spike and receptor binding domain are present for at least six months, confirming similar research by other CITF-funded researchers. In this publication, Dr. Nazy characterizes SARS-CoV-2 antibodies in recovered COVID-19 patients. This study was funded in [...]

2021-05-03T16:46:23-04:00May 4, 2021|Immune science|

Changes in immune cells in COVID patients could be a sign suggesting an unfavorable outcome

In a publication in the Journal of Clinical Investigation, Drs. Daniel Kaufmann and Andrés Finzi from Université de Montréal and collaborators, found that patients with acute SARS-CoV-2 infection have altered immune responses affecting the severity of symptoms and mortality. These findings may help clinicians identify patients at risk of unfavourable outcomes and shed light [...]

2021-04-26T15:37:27-04:00April 27, 2021|Immune science|

Immune cell analysis reveals that the amount of SARS-CoV-2 in the blood is a strong predictor of mortality

As SARS-CoV-2 continues to cause worldwide mortality, it has become increasingly important to define molecular markers that can identify individuals at risk of developing severe COVID-19, and even death. This could help in determining early preventive measures for improved patient outcomes. In a recent pre-print and therefore not yet peer-reviewed, CITF-funded researchers Drs. Daniel [...]

2021-03-29T20:47:05-04:00March 30, 2021|Immune science|

Using a glowing SARS-CoV-2 virus and mice to explain how antibodies protect from infection and severe disease

An international multisite research collaboration, including CITF-funded researcher Dr. Andrés Finzi from the Université de Montréal, used genetically modified mice that mimic COVID-19 disease in humans to study how antibodies from people who have recovered from COVID-19 could prevent severe disease in other people. The authors concluded that these antibodies were effective in not [...]

2021-04-07T11:24:49-04:00March 30, 2021|Immune science|

Why do some people experience mild COVID-19 symptoms and others have severe illness? Pre-existing antibodies could explain the range of COVID-19 illness

CITF-funded researcher Dr. Pascal Lavoie from the University of British Columbia and his collaborators are suggesting that the presence of antibodies to SARS-CoV-2 may not necessarily indicate a previous infection. Using highly sensitive tests, they discovered pre-existing antibodies to SARS-CoV-2 in many uninfected adults. The study was funded in part by the COVID-19 Immunity [...]

2021-03-23T10:58:27-04:00March 23, 2021|Immune science|

A novel mechanism leading to blood clot formation found in severely ill COVID-19 patients

Dr. Ishac Nazy and the McMaster Platelet Immunology Laboratory have found some of the reasons behind why some patients with severe COVID-19 have blood clots. The team found that blood from critically ill COVID-19 patients contains molecules that can activate cells involved in blood clotting. This study was supported by the Canadian Institutes of [...]

2021-03-23T10:19:07-04:00March 23, 2021|Immune science|
Go to Top